A selective cyclooxygenase-2 inhibitor (etodolac) prevents spontaneous biliary tumorigenesis in a hamster bilioenterostomy model

European Surgical Research

Volumn 52, Issue 1-2, 2014, Pages 73-82

  Kitasato, Amane ^a   Kuroki, Tamotsu ^a   Adachi, Tomohiko ^a   Ono, Shinichiro ^a   Tanaka, Takayuki ^a   Tsuneoka, Noritsugu ^a   Hirabaru, Masataka ^a   Takatsuki, Mitsuhisa ^a   Eguchi, Susumu ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Biliary carcinogenesis; Chemoprevention; Cyclooxygenase 2; Etodolac; Selective cyclooxygenase 2 inhibitor

Indexed keywords

CYCLINE; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; PROSTAGLANDIN E2; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CANCER; BILIARY TUMORIGENESIS; BILIOENTEROSTOMY; CANCER MODEL; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CHOLANGITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENTEROSTOMY; FEMALE; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SYRIAN HAMSTER; ADVERSE EFFECTS; ANIMAL; AUDIOVISUAL EQUIPMENT; BILE DUCT; BILE DUCT BYPASS; BILIARY TRACT NEOPLASMS; BILIARY TRACT SURGERY; COMPLICATION; DRUG EFFECTS; HAMSTER; LIVER; MESOCRICETUS; METABOLISM; PATHOLOGY; CHEMOPROPHYLAXIS; CHOLEDOCHOJEJUNOSTOMY; HEPATOBILIARY SYSTEM; HEPATOBILIARY SYSTEM CARCINOGENESIS; HEPATOBILIARY SYSTEM TUMOR; LABELING INDEX; PROTEIN EXPRESSION;

ANIMALS; ANTICARCINOGENIC AGENTS; BILE DUCTS; BILIARY TRACT NEOPLASMS; BILIARY TRACT SURGICAL PROCEDURES; CHOLANGITIS; CHOLEDOCHOSTOMY; CRICETINAE; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENTEROSTOMY; ETODOLAC; FEMALE; LIVER; MESOCRICETUS; MODELS, ANATOMIC; MODELS, ANIMAL;

EID: 84899776606     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000362542     Document Type: Article

References (31)

1. Watanabe Y, Toki A, Todani T: Bile duct cancer developed after cyst excision for choledochal cyst. J HepatobiliaryPancreat Surg 1999; 6: 207-212.
2. Russell W: Late bile duct cancer complicating biliary enteric anastomosis for benign disease. Am J Surg 1999;177: 472-474.
3. Kitajima T, Tajima Y, Onizuka S, Matsuzaki S, Matsuo K, Kanematsu T: Linkage of persistent cholangitis afterbilioenterostomy with biliary carcinogenesis in hamsters. J Exp Clin Cancer Res 2000; 19: 453-458.
4. Kitajima T, Tajima Y, Matsuzaki S, Kuroki T, Fukuda K, Kanematsu T: Acceleration of spontaneous biliary carcinogenesisin hamsters by bilioenterostomy. Carcinogenesis 2003; 24: 133-137.
5. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tanq BD, Bai AH, Sung JJ: Chemoprevention of gastric cancer by celecoxibin rats. Gut 2004; 53: 195-200.
6. Ricchi P, Zarrilli R, Palma A, Acquaviva AM: Nonsteroidal anti-inflammatory drugs in colorectal cancer: fromprevention to therapy. Br J Cancer 2003; 88: 803-807.
7. Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Naqano H, Umeshita K, Sakon M, MatsuuraN, Nakamori S, Monden M: Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelialcells and bile duct neoplasm. Hepatology 2001; 34: 638-650.
8. Chariyalertask S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Furstenberger G, Marks F, Muller-DeckerK: Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001; 48:80-86.
9. Tsuneoka N, Tajima Y, Kitazato A, Fukuda K, Kitaijma T, Kuroki T, Onizuka S, Kanematsu T: Chemopreventativeeffect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis inhamsters. Carcinogenesis 2005; 26: 465-469.
10. Takahashi M, Pour P, Althoff J, Donnelly T: The pancreas of the Syrian hamster (Mesocricetus auratua). LabAnim Sci 1977; 27: 336-342.
11. Singhal AK, Finver-Sadowsky J, McSherry CK, Mosbach EH: Effect of cholesterol and bile acids on the regulationof cholesterol mechanism in hamster. Biochem Biophys Acta 1983; 752: 214-222.
12. Rinderknecht H, Maset R, Collias K, Carmack C: Pancreatic secretory profiles of protein, digestive, and lysosomalenzymes in Syrian golden hamster. Effect of secretin and cholecystokinin. Dig Dis Sci 1983; 28: 518-525.
13. Turusov V, Mohr U (eds): Pathology of Tumors in Laboratory Animals: Tumors of the Liver. Volume III-Tumors of the Hamster. Lyon, International Agency for Research on Cancer, 1996, pp 79-108.
14. Mishima T, Tajima Y, Kuroki T, Kosaka T, Adachi T, Kitasato A, Tsuneoka N, Kitajima T, Kanematsu T: Chemopreventiveeffect of an inducible nitric oxide synthase inhibitor, ONO-1714, on inflammation-associatedbiliary carcinogenesis in hamsters. Carcinogenesis 2009; 30: 1763-1767.
15. Sirica AE, Lai GH, Zhang Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeuticstrategies. J Gastroenterol Hepatol 2001; 16: 363-372.
16. Sirica AE: Cholangiocarcinoma: molecular targeting strategy for chemoprevention and therapy. Hepatology2005; 41: 5-15.
17. Wu T: Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005;1755: 135-150.
18. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic susceptibilityby inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res2002; 62: 6323-6328.
19. Han C, Leng J, Demetris AJ, Wu T: Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidencefor cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21 waf1/cip1 and p27 kip1 andcell cycle arrest. Cancer Res 2004; 64: 1369-1376.
20. Yeh CN, Chiang KC, Juang HH, Pang JHS, Yu CS, Lin KJ, Yeh TS, Jan YY: Reappraisal of the therapeutic role ofcelecoxib in cholangiocarcinoma. PLoS One 2013; 8:e69928.
21. Han T, Wu T: Cyclooxygenase-2 derived prostaglandin E2 promotes human cholangiocarcinoma cell growthand invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. JBiol Chem 2005; 280: 24053-24063.
22. Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T: Cyclooxygenase-2-derived prostaglandin E2 activates β-cateninin human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by ω3 polyunsaturatedfatty acids. Cancer Res 2008; 68: 553-560.
23. Choi HJ, Kim HJ, Choi JH: Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.Hepatogastroenterology 2009; 56: 606-609.
24. Dongdong LU, Han C, Wu T: Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimentalcholangiocarcinogenesis and tumor progression. Gastroenterology 2011; 140: 2084-2094.
25. Eguchi H, Iwaki K, Shibata K, Ogawa T, Ohta M, Kitano S: Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases andnuclear factor kappa B. J Hepatobiliary Pancreat Sci 2011; 18: 147-153.
26. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol1971; 231: 232-235.
27. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitroanalysis. Proc Natl Acad Sci USA 1999; 96: 7563-7568.
28. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors.JAMA 2001; 286: 954-959.
29. White WB, Faich G, Wheiton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB: Comparison of thromboembolicevents in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofenor diclofenac. Am J Cardiol 2002; 89: 425-430.
30. Vanchieri C: Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004; 96: 1734-1735.
31. Fitzgerald GA: Coxibs and cardiovascular diseases. N Engl J Med 2004; 351: 1709-1711.